CORD-19:02533ec56945ea7e9e80eb9713707fd709de5c03 / 8333-8550 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/02533ec56945ea7e9e80eb9713707fd709de5c03","sourcedb":"CORD-19","sourceid":"02533ec56945ea7e9e80eb9713707fd709de5c03","text":"Se debe considerar su inicio de forma individualizada en pacientes que asocien otros factores protrombóticos, como talasemia, disminución de la proteína C, antitrombina iii o presencia de un catéter venoso central 1 .","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T57","span":{"begin":0,"end":217},"obj":"Sentence"},{"id":"TextSentencer_T57","span":{"begin":0,"end":217},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T57","pred":"source","obj":"CORD-19-Sentences"},{"subj":"TextSentencer_T57","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T57","span":{"begin":0,"end":217},"obj":"Sentence"}],"attributes":[{"subj":"T57","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T1","span":{"begin":206,"end":215},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_3010045"},{"subj":"T1","pred":"source","obj":"CORD-19-PD-UBERON"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93ecd9","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ecbf93"},{"id":"CORD-19-PD-UBERON","color":"#a593ec"}]}]}}